Breaking News, Collaborations & Alliances

SeraNovo, AstraZeneca Close Multi-compound Deal

Will leverage SeraNovo's technology to enhance the bioavailability of poorly soluble Active Pharmaceutical Ingredients.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

SeraNovo, based in Leiden, The Netherlands, closed a multi-compound deal with AstraZeneca.   Niall Hodgins, Chief Executive Officer of SeraNovo said, “SeraNovo has grown substantially in recent years in terms of our technical capabilities and worldwide customer base. It is great to be able to share news of one of our most important collaborations with such a historic company. Our technology will again be used to drive important therapies to patients. We look forward to a long and prosperous re...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters